Press release
Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
A lawsuit was filed on behalf of investors in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shares.
Investors who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) have certain options and for certain investors are short and strict deadlines running. Deadline: February 7, 2025. NASDAQ: KYTX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Emeryville, CA based Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead product candidate is KYV-101.
In early February 2024, Kyverna Therapeutics, Inc conducted its initial public offering (IPO). Kyverna Therapeutics, Inc sold over 16 million shares at $22 per share. Since then shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) declined to as low as $3.94 per share on November 19, 2024.
The plaintiff claims that the registration statement and prospectus used to effectuate the Company's IPO misstated and/or omitted facts concerning the results of the Company's ongoing evaluation of KYV-101 in clinical trials, that the Company touted patient "improvement" in certain indicators while failing to disclose adverse data regarding one of Kyverna's trials, which adverse data was known to the Company at the time of the IPO, and that as a result, investors purchased Kyverna shares at artificially inflated prices.
Those who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) here
News-ID: 3847903 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Tronox Holdings plc (N …
An investor, who purchased shares of Tronox Holdings plc (NYSE: TROX), filed a lawsuit over alleged violations of Federal Securities Laws by Tronox Holdings plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Tronox Holdings plc (NYSE: TROX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 3, 2025. NYSE: TROX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Investors in Petco Health and Wellness Company, Inc. …
An investigation was announced for current long-term investors in shares of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) concerning potential breaches of fiduciary duties by certain directors of Petco Health and Wellness Company, Inc.
Investors who are current long term investors in Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation…
Investigation announced for Long-Term Investors in RxSight, Inc. (NASDAQ: RXST) …
An investigation was announced for current long-term investors in shares of RxSight, Inc. (NASDAQ: RXST) concerning potential breaches of fiduciary duties by certain directors of RxSight, Inc.
Investors who are current long term investors in RxSight, Inc. (NASDAQ: RXST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: RXST…
Tesla, Inc. (NASDAQ: TSLA) Investor Alert: Deadline in Lawsuit on October 3, 202 …
A deadline is coming up on October 3, 2025 in the lawsuit filed for certain investors of Tesla, Inc. (NASDAQ: TSLA) over alleged securities laws violations by Tesla, Inc.
Investors who purchased shares of Tesla, Inc. (NASDAQ: TSLA) have certain options and there are strict and short deadlines running. Deadline: October 3, 2025. Tesla, Inc. (NASDAQ: TSLA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Kyverna
Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hof …
DelveInsight's, "Lupus Nephritis - Pipeline Insight, 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Lupus Nephritis pipeline involves over 35…
Investigation announced for Long-Term Investors in shares of Kyverna Therapeutic …
An investigation was announced for long-term investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) concerning potential breaches of fiduciary duties by certain directors and officers of Kyverna Therapeutics, Inc.
Investors who are current long term investors in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Vasculitis Pipeline: Pioneering Progress with 25+ Leading Companies Developing G …
The Vasculitis market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Mitsubishi Tanabe Pharma Corporation, Yake Biotechnology, and Kyverna Therapeutics. These industry pioneers are transforming treatment strategies and redefining the future of Vasculitis, bringing new hope to patients worldwide.
DelveInsight's "Vasculitis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Vasculitis market. The report covers disease insights, treatment…
Systemic Sclerosis Market on Track for Major Expansion by 2034, According to Del …
The Key Systemic Sclerosis Companies in the market include- Kyowa Hakko Kirin, AstraZeneca, Biocad, Boehringer Ingelheim, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Maruho Co., Ltd., Amgen, Cabaletta Bio, Kyverna Therapeutics, Lawson Health Research Institute, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Genentech, Inc., Changchun GeneScience Pharmaceutical, aTyr Pharma, Inc., Bristol-Myers Squibb, and others.
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Systemic Sclerosis, historical and…
Scleroderma Pipeline: Pioneering Progress with 40+ Leading Companies Developing …
The Scleroderma market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Certa Therapeutics, Argenx, Cumberland Pharmaceuticals, Sanofi, Amgen, Genentech, Cabaletta Bio, and Kyverna Therapeutics. These industry pioneers are transforming treatment strategies and redefining the future of Scleroderma, bringing new hope to patients worldwide.
DelveInsight's "Scleroderma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Scleroderma market. The report…
Lupus Nephritis Clinical and Non-Clinical Studies, Key Companies, Therapeutic As …
Lupus Nephritis Pipeline constitutes 35+ key companies continuously working towards developing 40+ Lupus Nephritis treatment therapies, analyzes DelveInsight.
Lupus Nephritis Overview:
Lupus Nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that disrupts immune tolerance and leads to systemic autoimmunity, damaging multiple organs.
SLE affects approximately 7.4-159.4 people per 100,000, with a prevalence of 1.4% to 21.9%. LN, a type of glomerulonephritis, causes inflammation and scarring…
